RX
Recursion Pharmaceuticals
RXRX · NASDAQ
$3.63 +6.45% (+$0.22)
1M +12.73%
Market Cap $1.80B
P/E Ratio -
Div. Yield -
ROE 50.41%
Piotroski F-Score Weak
3/9Valuation
44 /100
Fair P/B 1.97x
P/S 32.90x
EV/FFO N/A
Growth
100 /100
Growing Book val. growth 32.53%
Rev. growth 23.46%
FCF growth N/A
Profitability
0 /100
Weak Op. margin 991.72%
Gross margin 46.66%
FCF margin 645.82%
Quality
1 /100
Poor ROA 42.79%
ROIC 48.34%
Asset turnover 0.05x
Debt
69 /100
Low Int. coverage -350.41x
Debt/Equity 0.07x
Current ratio 5.03x
Stability
75 /100
Stable EPS volatility 15.90%
Beta 1.07x
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o RXRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Najat Khan
Employees
600
Headquarters
Salt Lake City
Prihajajoči dogodki
04 NOV.
Earnings
Upcoming earnings report